Kymab strengthens and expands capabilities through Board appointments and Executive promotions
29 September 2014 | By Kymab
Following a US$40 million Series B investment from The Wellcome Trust and the Bill & Melinda Gates Foundation...
List view / Grid view
News
Abbott completes acquisition of CFR Pharmaceuticals
29 September 2014 | By Abbott
Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets...
European CHMP adopts positive opinion for Gilead’s Harvoni® (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C infection in adults
29 September 2014 | By Gilead
Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion on the company’s Marketing Authorization Application for Harvoni®...
Nintedanib* receives positive CHMP opinion for second-line treatment of patients with adenocarcinoma of the lung
29 September 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the approval of nintedanib*...
Roche’s investigational combination of cobimetinib plus Zelboraf (vemurafenib) provided significant benefit to people with advanced melanoma over Zelboraf alone
29 September 2014 | By Roche
Roche announced positive data from the coBRIM Phase III study...
Positive Phase 3 data for Opdivo (nivolumab) in advanced melanoma patients previously treated with yervoy (ipilimumab) presented at the ESMO 2014 Congress; first phase 3 results presented for a PD-1 immune checkpoint inhibitor
29 September 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced positive results from CheckMate -037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma who were previously treated with Yervoy (ipilimumab)...
Vela Diagnostics launches first CE-IVD Next-Generation Sequencing oncology Panel for melanoma testing on the automated Sentosa® NGS workflow
26 September 2014 | By Vela Diagnostics
Vela Diagnostics announced the CE-IVD launch of the Sentosa® SQ Melanoma Panel for Next-Generation Sequencing (NGS)- based gene sequence variant detection and identification...
Roche launches Global Access Program for HIV viral load testing
26 September 2014 | By Roche
Roche announced the launch of a new Global Access Program for HIV viral load testing...
Pfizer completes acquisition of InnoPharma
26 September 2014 | By Pfizer
Pfizer Inc. announced that it has completed its acquisition of the pharmaceutical development company, InnoPharma, Inc., following receipt of United States regulatory approval from all government authorities required by the agreement and other closing conditions...
Almirall’s aclidinium bromide/formoterol fumarate recommended for approval in Europe to treat COPD
26 September 2014 | By Almirall S.A
Almirall S.A. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for the regulatory approval of Duaklir® Genuair® (aclidinium bromide/formoterol fumarate) in all EU member states...
Novo Nordisk establishes new obesity research unit in Seattle
26 September 2014 | By Novo Nordisk
Novo Nordisk announced that the company will establish a new obesity research unit in Seattle, Washington, in the US...
AbbVie’s HUMIRA® (adalimumab) receives U.S. FDA approval for the treatment of pediatric patients with moderately to severely active Crohn’s disease
26 September 2014 | By AbbVie
AbbVie announced that the U.S. Food and Drug Administration has approved HUMIRA® (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough...
Dolomite and Lab on a Chip launch video competition to win $2,500 of microfluidic equipment
25 September 2014 | By kdm communications
Microfluidics specialist Dolomite has teamed up with Lab on a Chip and the Chemical and Biological Microsystems Society to create the first ever MicroTAS Video Competition...
Roche’s Avastin and Xeloda show benefit for women with HER2-negative metastatic breast cancer in two new Phase III studies
25 September 2014 | By Roche
Roche announced results from the phase III IMELDA study which showed that the combination of Avastin (bevacizumab) plus Xeloda (capecitabine) chemotherapy as a maintenance treatment following initial induction treatment with Avastin-based therapy resulted in clinically meaningful gains in overall survival...
GlaxoSmithKline plc appoints Sir Philip Hampton to the Board of Directors
25 September 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that Sir Philip Hampton will join the Board of the company as Non-Executive Director from 1 January 2015 and will become Deputy Chairman with effect from 1 April 2015...
